^
Association details:
| Biomarker: | POTEE mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Published date:
06/15/2023
Excerpt:
In the merged cohort, patients with POTEE-mutation (POTEE-Mut) had a significantly higher objective response rate (ORR) (100% vs 27.7%; P < 0.001) and longer progression-free survival (PFS) (P = 0.001; HR 0.08; 95% CI 0.01 - 0.54) compared to patients with POTEE wild-type (POTEE-WT) in NSCLC. Also, patients with POTEE-Mut showed higher ORR (100% vs 27.2%; P < 0.001) and longer PFS (P = 0.001; HR 0.07; 95% CI 0.01 - 0.52) in lung adenocarcinoma (LUAD).
DOI:
10.1007/s10637-023-01375-2